Molecular glues have emerged as an exciting new class of agents in drug discovery, offering a novel mechanism to modulate protein function, both as protein degraders and for other therapeutic targets. Unlike traditional drugs that inhibit or block protein activity, molecular glues enhance or induce new protein-protein interactions (PPIs), allowing them to activate biological pathways rather than suppressing them. For instance, the natural compound Rapamycin has been used as an immunosuppressant for decades. It binds at the interface of mTOR and FKBP12 and increases the interaction between these two proteins…